Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02789384

CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

This is a prospective observational biomarker study including patients with non-metastatic, soft-tissue sarcomas (STS) for whom neoadjuvant chemotherapy is considered as the best option by the multidisciplinary sarcoma team of one of the participating centers.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Soft-tissue Sarcomas Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Sarcoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Bergonié, Bordeaux, France

Loading trial locations.

About this study

Even when retrospective statistical identification for a biomarker has been achieved, the ultimate proof of its usefulness in the clinic still requires prospective evidence. Our prospective study aims to validate the prognosis value of the CINSARC signature in a prospective way. Moreover, the neoadjuvant setting is an ideal one to identify molecular predictive factors of sensitivity to chemotherapy by correlating tumor response with genetic profile of STS. Moreover, molecular profiling of treatment-refractory tumor cells may reveal alterations that are associated with drug resistance, metastatic recurrence and disease progression. The identifications of such factors in the neoadjuvant setting may help to improve the management of STS patients in the adjuvant and metastatic settings

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically confirmed soft-tissue sarcoma by central review, except if the diagnosis was already confirmed by the RRePS (Réseau de Référence en Pathologie des Sarcomes et des Viscères) Network,
  • Available archived frozen tumor tissue sample or patient consenting to undergo a biopsy of the tumour for research purpose,
  • Non-metastatic disease, for which the use of chemotherapy to "downstage" the sarcoma prior to surgery, is assumed to result in better local tumor control by the multidisciplinary sarcoma team of one of the French reference centers involved in this study,
  • Age ≥ 18 years,
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1,
  • Measurable disease according to RECIST v1.1 outside any previously irradiated field,
  • Neoadjuvant anthracycline-based chemotherapy proposed as the best option by the multidisciplinary sarcoma team of one of the French reference centers involved in this study,
  • No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
  • Voluntarily signed and dated written informed consents prior to any study specific procedure,
  • Patients with a social security in compliance with the French Law relating to biomedical research (Article 1121-11 of French Public Health Code).

Exclusion criteria

  • Pathological diagnosis different from a soft-tissue sarcoma,
  • Histological subtypes: well-differentiated liposarcoma, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell sarcoma, rhabdomyosarcoma,
  • Previous treatment for the sarcoma,
  • Contra-indication precluding the administration of chemotherapy as assessed by the investigator,
  • Participation to a study involving a medical or therapeutic intervention in the last 30 days,
  • Previous enrolment in the present study,
  • Pregnant or breast feeding women,
  • Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.

Treatment and study plan

Procedure/Surgery

Other

Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.

For each patient:

  • Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling
  • Blood samples will be obtained for genetic profiling and assessment of markers.

The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.

All patients should be managed according to the usual medical practices.

Primary outcomes

  1. Assessment of antitumor activity of neoadjuvant anthracycline based chemotherapy. Efficacy will be defined based on complete response, partial response and stable disease observed during treatment following RECIST v1.1 criteria.

    Time frame: participants will be followed for the duration of treatment, an expected average of 6-months

Secondary outcomes

  1. Efficacy of neoadjuvant anthracycline based chemotherapy in terms of proportion of tumour cells identified on the surgical specimen

    Time frame: an expected average of 6 months

  2. Association of the CINSARC signature and histological response based on the proportion of tumour cells identified on the surgical specimen

    Time frame: an expected average of 6 months

  3. Patient's classification by CINSARC signature. Patients will be classified as either low risk CINSARC or high risk

    Time frame: 6 months

  4. Metastasis-free survial is defined following recent guidelines for the definition of survival endpoints in sarcoma trials (Bellera et al. Annals Oncol 2014.

    Time frame: 3 years

  5. 3 -year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause).

    Time frame: 3 years

  6. Histological response is defined using both 3 histological parameters: proportion of recognizable tumor cells, fibrosis and necrosis in the surgical specimen.

    Time frame: an expected average of 6 months

  7. Identification of molecular mechanisms involved in intrinsic resistance to chemotherapy by correlating the transcriptome data with response to chemotherapy.

    Time frame: an expected average of 6 months

  8. Adverse events related to the biopsy procedure will be graded using the common toxicity criteria from the NCI v4.0.

    Time frame: during 7 days after biopsy

Study contacts

Contact information is provided by the study sponsor or research team.

Antoine ITALIANO, MD,PhD

CONTACT

[email protected]

Simone MATHOULIN-PELISSIER, MD,PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Institut Bergonié

Other

Collaborators

  • Ministry of Health, France
  • National Cancer Institute, France

Registry information

Official study title

Prognostic Value of the CINSARC (Complexity Index in Sarcoma) Signature and Correlation With Chemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. (NEOSarcomics )

Acronym: NEOSarcomics

Important dates

Study start
2016
Primary completion
2026
Study completion
2027
First posted
Jun 3, 2016
Registry last updated
Dec 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.